Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.32 |
| ▸ | SGK1 | O00141 | 5/20 | 0.31 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | CCR4 | P51679 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30684744 | 0.90 | CCR4 (0.36) | PIK3CAPIK3CDPIK3CBPIK3CGCYP2C9 | |
| SCHEMBL21596669 | 0.90 | CCR4 (0.36) | PIK3CAPIK3CDPIK3CBPIK3CGCYP2C9 | |
| SCHEMBL23620168 | 0.89 | PIK3CA (0.30) | PIK3CA | |
| SCHEMBL21596665 | 0.86 | CCR4 (0.40) | PIK3CAPIK3CDPIK3CBPIK3CGSGK1 | |
| SCHEMBL30991319 | 0.86 | CCR4 (0.40) | PIK3CAPIK3CDPIK3CBPIK3CGSGK1 | |
| SCHEMBL21596689 | 0.86 | CCR2 (0.36) | CYP2C9CYP2C19SGK1SLC40A1CCR2 | |
| SCHEMBL29829479 | 0.86 | CCR2 (0.36) | CYP2C9CYP2C19SGK1SLC40A1CCR2 | |
| SCHEMBL21596692 | 0.82 | — | — | |
| SCHEMBL30727437 | 0.80 | PIK3CA (0.35) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL27041091 | 0.80 | PIK3CA (0.35) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112469710-B | Pyridyl and pyrazinyl- (aza) indole sulfonamides | 优时比制药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| EP-4074703-B1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2023-11-29 | — | — | EP | disclosed |
| EP-4074703-A1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB Pharma GmbH (DE) | 2022-10-19 | — | — | EP | disclosed |
| EP-3810591-B1 | PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2022-08-10 | — | — | EP | disclosed |
| US-20210206749-A1 | Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides | UCB PHARMA GMBH (DE) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206749-A1 | Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides | GPR17, GPR18, GPR119 | PIK3CA 2852/4885PIK3CD 2941/4885PIK3CB 2909/4885 |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | GPR17, GPR18, GPR119 | PIK3CA 2852/4885PIK3CD 2941/4885PIK3CB 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.